ReviewActa oncologica (Stockholm, Sweden)2011
Tumor markers in prostate cancer I: blood-based markers.
Review in Acta oncologica (Stockholm, Sweden), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03397030 (Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer), which is not on this map. Cited by 73 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer
Who cites it
73 citing papers in PubMed, 4 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis.Cancer medicine · 2020Pooled it
- Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis.International journal of clinical oncology · 2020Pooled it
- Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis.International journal of clinical oncology · 2020Pooled it
- Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2019Pooled it
- Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.Prostate cancer and prostatic diseases · 2020Trial
- Prospective evaluation of the performance of [European journal of nuclear medicine and molecular imaging · 2019Trial
- MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214.PloS one · 2013Trial
- Prospective Intraindividual Comparison of Ga-68 PSMA and F-18 FDG Dual-Tracer PET/CT Imaging in Evaluation of High-Grade Prostate Cancer.World journal of nuclear medicine · 2026Article
- Integrative advances in biomarker-driven prostate cancer management from genomic discovery to precision oncology.Discover oncology · 2026Review
- Early response monitoring during [European journal of nuclear medicine and molecular imaging · 2024Observational
- Prognostic value of the HALP score in metastatic castration-resistant prostate cancer: an analysis combined with time to castration resistance.Frontiers in oncology · 2024Article
- Article
- Multi-marker risk-based screening for prostate cancer.Journal of medical screening · 2022Article
- Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients.Life (Basel, Switzerland) · 2022Article
- Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.Molecular carcinogenesis · 2022Article
- The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Biochemical Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy.Frontiers in oncology · 2022Article
- Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy.International journal of clinical oncology · 2021Article
- Multiplexed Prostate Cancer Companion Diagnostic Devices.Sensors (Basel, Switzerland) · 2021Review
- Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [Prostate cancer and prostatic diseases · 2021Article
- Predicting Metastasis in Melanoma by Enumerating Circulating Tumor Cells Using Photoacoustic Flow Cytometry.Lasers in surgery and medicine · 2021Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
unlabelledThe introduction of total prostate specific antigen (total PSA) testing in blood has revolutionized the detection and management of men with prostate cancer (PCa). The objective of this review was to discuss the challenges of PCa biomarker research, definition of the type of PCa biomarkers, the statistical considerations for biomarker discovery and validation, and to review the literature regarding total PSA velocity and novel blood-based biomarkers.
methodsAn English-language literature review of the Medline database (1990 to August 2010) of published data on blood-based biomarkers and PCa was undertaken.
resultsThe inherent biological variability of total PSA levels affects the interpretation of any single result. Men who will eventually develop PCa have increased total PSA levels years or decades before the cancer is diagnosed. Total PSA velocity improves predictiveness of total PSA only marginally, limiting its value for PCa screening and prognostication. The combination of PSA molecular forms and other biomarkers improve PCa detection substantially. Several novel blood-based biomarkers such as human glandular kallikrein 2 (hK2), urokinase plasminogen activator (uPA) and its receptor (uPAR), transforming growth factor-beta 1 (TGF-β1); interleukin-6 (IL-6) and its receptor (IL-6R) may help PCa diagnosis, staging, prognostication, and monitoring. Panels of biomarkers that capture the biologic potential of PCa are in the process of being validated for PCa prognostication.
conclusionsPSA is a strong prognostic marker for long-term risk of clinically relevant cancer. However, there is a need for novel biomarkers that aid clinical decision making about biopsy and initial treatment. There is no doubt that progress will continue based on the integrated collaboration of researchers, clinicians and biomedical firms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.